Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970292 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
A Phase 3 study of Schizophrenia, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 396
- Enrollment target
- 20
- Study locations
NCT02970292: Completed Phase 3 study of Schizophrenia, sponsored by ACADIA Pharmaceuticals.
NCT02970292 is a Phase 3 study of Schizophrenia that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 396 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02970292, a Phase 3 study of Schizophrenia, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 396 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Primary Outcome
The PANSS is a 30-item scale used to evaluate the presence, absence, and severity of schizophrenia symptoms. The 30 items are arranged as 7 positive symptom items (P1 to P7), 7 negative symptom items (N1 to N7), and 16 general psychopathology symptom items (G1 to G16). Items are scored over the past week (7 days) on a 7-point scale ranging from 1 (absent) to 7 (extreme). The PANSS total score can range from a minimum of 30 to a maximum of 210, where a higher score signifies greater severity of s
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pimavanserin
Study Locations (20)
California
- - Bellflower
- - Cerritos
- - Culver City
- - Lemon Grove
- - Long Beach
- - San Diego
- - San Diego
- - Santa Ana
- - Torrance
Florida
- - Boca Raton
- - Lauderhill
- - Miami
Illinois
- - Chicago
- - Chicago
- - Hoffman Estates
Arkansas
- - Little Rock
- - Rogers
Georgia
- - Atlanta
- - Atlanta
Arizona
- - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2016-10-26 |
| Est. Completion | 2019-06-25 |
| Phase | Phase 3 |
What the finished NCT02970292 record still lists
NCT02970292 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02970292 names 20 study sites across 6 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02970292 about?
NCT02970292 is a clinical study titled "Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)". To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
What is the current status of trial NCT02970292?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 396 participants. The study started on 2016-10-26. Estimated completion is 2019-06-25.
What conditions does trial NCT02970292 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02970292?
The interventions under investigation include: Placebo (DRUG), Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT02970292?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02970292 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02970292's enrollment target sits among peer trials
396 46th of 315 higher than 270 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI